Literature DB >> 9223544

Evaluation of the antimyotonic activity of mexiletine and some new analogs on sodium currents of single muscle fibers and on the abnormal excitability of the myotonic ADR mouse.

A De Luca1, S Pierno, F Natuzzi, C Franchini, A Duranti, G Lentini, V Tortorella, H Jockusch, D C Camerino.   

Abstract

To search for use-dependent sodium channel blockers to selectively solve skeletal muscle hyperexcitability in hereditary myotonias, mexiletine (MEX; compound I) and its newly synthetized analogs, 2-(4-chloro-2-methylphenoxy)-benzenethanamine (compound II) and (-)-S-3-(2,6-dimethylphenoxy)-2-methylpropanamine (compound III), were tested on intercostal muscle fibers from the myotonic ADR mouse through use of the standard current-clamp microelectrode technique. In parallel, the effects of these compounds on the sodium channels were measured on frog muscle fibers under voltage-clamp conditions. The tonic and use-dependent blocks of peak sodium currents (I(Namax)) produced by each compound were evaluated by using a single depolarizing pulse and a pulse train at 10 Hz frequency, respectively. At 10 and 50 microM, MEX decreased the occurrence of spontaneous excitability in myotonic muscle fibers; 100 microM was required to decrease the amplitude of the action potential and the stimulus-induced firing of the membrane as well as to increase the threshold for generation of action potential. At 300 microM, MEX decreased the latency of the action potential and increased the threshold current to elicit a single action potential. MEX produced a tonic block of I(Namax) with an half-maximal concentration (IC50) of 83 microM, but the IC50 value for use-dependent block was 3-fold lower. Compound III, which differs from MEX in that it has a longer alkyl chain, similarly blocked first the spontaneous and then the stimulus-evoked excitability of myotonic muscle fibers but at 2-fold lower concentrations than MEX. Compound III was less potent than MEX in producing a tonic block of I(Namax) (IC50 = 108 microM) but was a strong use-dependent blocker with an IC50 close to 15 microM. The more lipophylic compound II irreversibly blocked both spontaneous and stimulus-evoked membrane excitability at concentrations as low as 10 microM and shortened the latency of the action potential in a concentration-dependent fashion. Compound II produced a potent tonic block of I(Namax) (IC50 = 30 microM), and its potency increased 2-fold during high-frequency stimulation. Both of the new analogs (compound II in particular), but not MEX, were less effective on the excitability parameters of striated fibers of healthy vs. ADR mice, a characteristic that increases their interest as potential antimyotonic agents.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223544

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Mexiletine block of disease-associated mutations in S6 segments of the human skeletal muscle Na(+) channel.

Authors:  M P Takahashi; S C Cannon
Journal:  J Physiol       Date:  2001-12-15       Impact factor: 5.182

2.  Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na(+) channels enhancing the antimyotonic activity in vivo.

Authors:  S Talon; A De Luca; M De Bellis; J F Desaphy; G Lentini; A Scilimati; F Corbo; C Franchini; P Tortorella; H Jockusch; D Conte Camerino
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

3.  Bioisosteric Modification of To042: Synthesis and Evaluation of Promising Use-Dependent Inhibitors of Voltage-Gated Sodium Channels.

Authors:  Gualtiero Milani; Maria Maddalena Cavalluzzi; Concetta Altamura; Antonella Santoro; Mariagrazia Perrone; Marilena Muraglia; Nicola Antonio Colabufo; Filomena Corbo; Elisabetta Casalino; Carlo Franchini; Isabella Pisano; Jean-François Desaphy; Antonio Carrieri; Alessia Carocci; Giovanni Lentini
Journal:  ChemMedChem       Date:  2021-10-05       Impact factor: 3.540

4.  Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile.

Authors:  Annamaria De Luca; Sophie Talon; Michela De Bellis; Jean-François Desaphy; Carlo Franchini; Giovanni Lentini; Alessia Catalano; Filomena Corbo; Vincenzo Tortorella; Diana Conte-Camerino
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-25       Impact factor: 3.000

5.  A practical and efficient route for the highly enantioselective synthesis of mexiletine analogues and novel beta-thiophenoxy and pyridyl ethers.

Authors:  Kun Huang; Margarita Ortiz-Marciales; Viatcheslav Stepanenko; Melvin De Jesús; Wildeliz Correa
Journal:  J Org Chem       Date:  2008-08-09       Impact factor: 4.354

6.  Neuroprotective effect of mexiletine in the central nervous system of diabetic rats.

Authors:  Ozkan Ates; Suleyman R Cayli; Eyup Altinoz; Neslihan Yucel; Ayhan Kocak; Ozcan Tarim; Akif Durak; Yusuf Turkoz; Saim Yologlu
Journal:  Mol Cell Biochem       Date:  2006-03-16       Impact factor: 3.396

7.  Spiroborate ester-mediated asymmetric synthesis of beta-hydroxy ethers and its conversion to highly enantiopure beta-amino ethers.

Authors:  Kun Huang; Margarita Ortiz-Marciales; Wildeliz Correa; Edgardo Pomales; Xaira Y López
Journal:  J Org Chem       Date:  2009-06-05       Impact factor: 4.354

8.  Increased hindrance on the chiral carbon atom of mexiletine enhances the block of rat skeletal muscle Na+ channels in a model of myotonia induced by ATX.

Authors:  J F Desaphy; D Conte Camerino; C Franchini; G Lentini; V Tortorella; A De Luca
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

9.  Combined modifications of mexiletine pharmacophores for new lead blockers of Na(v)1.4 channels.

Authors:  Michela De Bellis; Annamaria De Luca; Jean F Desaphy; Roberta Carbonara; Judith A Heiny; Ann Kennedy; Alessia Carocci; Maria M Cavalluzzi; Giovanni Lentini; Carlo Franchini; Diana Conte Camerino
Journal:  Biophys J       Date:  2013-01-22       Impact factor: 4.033

10.  Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimyotonic activity.

Authors:  Michela De Bellis; Roberta Carbonara; Julien Roussel; Alessandro Farinato; Ada Massari; Sabata Pierno; Marilena Muraglia; Filomena Corbo; Carlo Franchini; Maria Rosaria Carratù; Annamaria De Luca; Diana Conte Camerino; Jean-François Desaphy
Journal:  Neuropharmacology       Date:  2016-10-13       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.